Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Starts China and US Trials of CD73 Immunotherapy

publication date: Feb 5, 2021

Shanghai I-Mab has started China and US trials of its CD73 antibody, uliledlimab, in combination with PD-(L)1 inhibitors. CD73 is thought to suppress immune responses in tumors. Uliledlimab works by inhibiting the adenosine pathway to inhibit CD73, which I-Mab expects will enhance the immune response of PD-(L)1 inhibitors. Overall, I-Mab is currently conducting three Phase I clinical trials in the US and China, plus another four China trials, mostly Phase II or III. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.